Sarepta Therapeutics (SRPT)
20.93
+0.48 (2.35%)
Upcoming Events
Latest Headlines
Selloff in this biotech stock is overdone – Mizuho
September 12, 2026 4:00 PM - StreetInsider
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
September 9, 2026 7:28 AM - StreetInsider
Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'
September 8, 2026 1:25 PM - StreetInsider
Mizuho Defends Sarepta Therapeutics (SRPT)
September 8, 2026 10:53 AM - StreetInsider
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
September 8, 2026 9:00 AM - BizWire
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026 4:30 PM - BizWire
Form 13F-HR Sarepta Therapeutics, For: Jun 30
August 14, 2026 6:10 AM - SEC Filing
Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC
August 13, 2026 1:39 PM - SEC Filing
Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP
August 7, 2026 10:55 AM - SEC Filing
Sarepta Therapeutics (SRPT) PT Lowered to $35 at Oppenheimer
August 6, 2026 8:37 AM - StreetInsider
Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue
August 5, 2026 4:35 PM - StreetInsider
Form 8-K Sarepta Therapeutics, For: Aug 05
August 5, 2026 4:07 PM - SEC Filing
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
August 5, 2026 4:05 PM - BizWire
Form 10-Q Sarepta Therapeutics, For: Jun 30
August 5, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
July 31, 2026 11:40 AM - SEC Filing
Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: BlackRock, Inc.
July 30, 2026 11:19 AM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL
July 29, 2026 8:05 PM - SEC Filing
Form 3 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL
July 29, 2026 8:00 PM - SEC Filing
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 29, 2026 5:00 PM - BizWire
Form S-8 Sarepta Therapeutics,
July 28, 2026 5:15 PM - SEC Filing
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
July 28, 2026 6:44 AM - StreetInsider
Form 8-K Sarepta Therapeutics, For: Jul 23
July 27, 2026 9:08 AM - SEC Filing
Sarepta Therapeutics names Michael Severino as new CEO
July 27, 2026 8:30 AM - StreetInsider
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
July 27, 2026 8:30 AM - BizWire
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
July 22, 2026 8:30 AM - BizWire
Sarepta Therapeutics (SRPT) PT Lowered to $20 at Piper Sandler
July 9, 2026 7:11 AM - StreetInsider
Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
July 8, 2026 5:07 PM - StreetInsider
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
July 1, 2026 6:58 AM - StreetInsider
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2026 4:25 PM - BizWire
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
June 30, 2026 11:00 AM - StreetInsider
FDA accepts Sarepta's applications to convert two DMD drugs to full approval
June 30, 2026 8:30 AM - StreetInsider
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026 8:30 AM - BizWire
Sarepta Therapeutics (SRPT) 5700 contracts of July 20 calls trade
June 18, 2026 6:11 AM - StreetInsider
Full Article List
